G1 Therapeutics Q1 2024 GAAP EPS $(0.20), Inline, Sales $14.476M Miss $15.259M Estimate
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics (NASDAQ:GTHX) reported Q1 2024 earnings with a GAAP EPS of $(0.20), meeting analyst estimates, and a 62.26% improvement from last year's $(0.53) per share. However, their sales of $14.476M fell short of the $15.259M estimate, a 5.13% miss, though it represents an 11.82% increase from the previous year.
May 01, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
G1 Therapeutics reported Q1 2024 earnings with EPS of $(0.20), in line with estimates, and sales of $14.476M, missing estimates but showing year-over-year growth.
The EPS meeting analyst estimates indicates stability, which could neutralize investor sentiment. However, the sales miss might cause some concern, but the year-over-year growth in sales could offset negative sentiment, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100